Cue Biopharma, Inc. 8-K

What Happened
Cue Biopharma, Inc. (CUE) announced its financial results for the quarter ended March 31, 2026 in a press release dated May 14, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed on May 14, 2026 (Item 2.02: Results of Operations and Financial Condition).

Key Details

• The press release reporting quarterly results is dated May 14, 2026 and covers the quarter ended March 31, 2026.
• The press release was furnished as Exhibit 99.1 to the Form 8-K (Item 9.01(d)).
• The Form 8-K was signed on May 14, 2026 by Shao‑Lee Lin, President and Chief Executive Officer (also serving as Interim Principal Financial Officer and Interim Principal Accounting Officer).
• The filing is an 8-K Item 2.02 disclosure (results of operations/financial condition); investors should review Exhibit 99.1 for the specific revenue, earnings, cash position, and any management commentary.

Why It Matters
This filing signals Cue Biopharma has publicly reported its latest quarterly financial results; those results (revenue, net income/loss, cash runway, and management commentary) can materially affect the stock and investor outlook. Retail investors should read the furnished press release (Exhibit 99.1) for the specific figures and any forward-looking statements or operational updates, and monitor subsequent investor materials or SEC filings for further detail.